Search Within

CHRONIC MYELOID LEUKEMIA (CML)

New Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Journal: Current Pharmaceutical Biotechnology
Volume: 7,Issue: 5
Page: 371-379
Authors: Shinya Kimura, Eishi Ashihara and Taira Maekawa

The Kinase Inhibitor Imatinib - An Immunosuppressive Drug?

Journal: Current Cancer Drug Targets
Volume: 7,Issue: 3
Page: 251-258
Authors: D. Wolf, H. Tilg, H. Rumpold, G. Gastl and A. M. Wolf

JAK2 as a Molecular Marker in Myeloproliferative Diseases

Journal: Cardiovascular & Hematological Agents in Medicinal Chemistry
Volume: 5,Issue: 3
Page: 198-203
Authors: R. Mata, D. Subira, A. Garcia-Raso and P. Llamas

Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions

Journal: Current Pharmaceutical Design
Volume: 11,Issue: 2
Page: 265-272
Authors: Eric X. Chen and Lillian L. Siu

Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients

Journal: Current Clinical Pharmacology
Volume: 3,Issue: 3
Page: 198-203
Authors: Stefan Pursche, Eberhard Schleyer, Malte von Bonin, Gerhard Ehninger, Samir Mustafa Said, Roland Prondzinsky, Thomas Illmer, Yanfeng Wang, Christian Hosius, Zariana Nikolova, Martin Bornhauser and Gregor Dresemann

Targeted Drugs in Chronic Myeloid Leukemia

Journal: Current Medicinal Chemistry
Volume: 15,Issue: 29
Page: 3036-3051
Authors: Joanna Gora-Tybor and Tadeusz Robak

Imatinib and Its Successors – How Modern Chemistry has Changed Drug Development

Journal: Current Pharmaceutical Design
Volume: 15,Issue: 2
Page: 120-133
Authors: Bernhard A. Muller

The Gamma Catenin/CBP Complex Maintains Survivin Transcription in β-catenin Deficient/Depleted Cancer Cells

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 2
Page: 213-225
Authors: Y.-M. Kim, H. Ma, V. G. Oehler, E. J. Gang, C. Nguyen, D. Masiello, H. Liu, Y. Zhao, J. Radich and M. Kahn

Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL

Journal: Current Drug Targets
Volume: 10,Issue: 6
Page: 530-536
Authors: Massimo Breccia and Giuliana Alimena

Valproic Acid in the Complex Therapy of Malignant Tumors

Journal: Current Drug Targets
Volume: 11,Issue: 3
Page: 361-379
Authors: J. Hrebackova, J. Hrabeta and T. Eckschlager

Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 10,Issue: 2
Page: 111-115
Authors: Yaoyu Chen, Cong Peng, Con Sullivan, Dongguang Li and Shaoguang Li

Combination Therapy with Arsenic Trioxide for Hematological Malignancies

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 10,Issue: 6
Page: 504-510
Authors: Shinichiro Takahashi

Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept

Journal: Current Cancer Drug Targets
Volume: 11,Issue: 1
Page: 56-71
Authors: P. Valent

Interferon alpha for Treatment of Chronic Myeloid Leukemia

Journal: Current Drug Targets
Volume: 12,Issue: 3
Page: 420-428
Authors: Bengt Simonsson, Henrik Hjorth-Hansen, Ole Weis Bjerrum and Kimmo Porkka

Omacetaxine as an Anticancer Therapeutic: What is Old is New Again

Journal: Current Pharmaceutical Design
Volume: 17,Issue: 1
Page: 59-64
Authors: Meir Wetzler and David Segal

Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation

Journal: Current Medicinal Chemistry
Volume: 18,Issue: 14
Page: 2146-2157
Authors: X. Y. Lu, Q. Cai and K. Ding

Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors

Journal: Current Medicinal Chemistry
Volume: 18,Issue: 19
Page: 2885-2892
Authors: I. Filippi, A. Naldini and F. Carraro

BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile

Journal: Current Medicinal Chemistry
Volume: 18,Issue: 19
Page: 2943-2959
Authors: F. Leonetti, A. Stefanachi, O. Nicolotti, M. Catto, L. Pisani, S. Cellamare and A. Carotti

Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity

Journal: Current Medicinal Chemistry
Volume: 18,Issue: 34
Page: 5174-5184
Authors: M. Krusch and H. R. Salih

Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone

Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 1,Issue: 3
Page: 347-355
Authors: Shinya Kimura

Dasatinib in the Treatment of Chronic Myeloid Leukemia

Journal: Current Signal Transduction Therapy
Volume: 6,Issue: 1
Page: 99-105
Authors: Joanna Gora-Tybor and Tadeusz Robak


Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 4
Page: 391-401
Authors: M. Breccia and G. Alimena

Emerging Therapies in Chronic Myeloid Leukemia

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 5
Page: 458-470
Authors: J. Gora-Tybor

New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia

Journal: Current Cancer Drug Targets
Volume: 12,Issue: 5
Page: 571-596
Authors: A. Stefanachi, F. Leonetti, O. Nicolotti, M. Catto, L. Pisani, S. Cellamare, C. Altomare and A. Carotti

On the Power of Additional and Complex Chromosomal Aberrations in CML

Journal: Current Genomics
Volume: 13,Issue: 6
Page: 471-476
Authors: Karin M. Greulich-Bode and Barbara Heinze

NFκB Pathway and microRNA-9 and -21 are Involved in Sensitivity to the Pterocarpanquinone LQB-118 in Different CML Cell Lines

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 15,Issue: 3
Page: 345-352
Authors: Fernanda Costas C. de Faria, Maria Eduarda Bento Leal, Paula Sabbo Bernardo, Paulo R.R. Costa and Raquel C. Maia

Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 7
Page: 735-748
Authors: Sophia Adamia, Patrick M. Pilarski, Michal Bar-Natan, Richard M. Stone and James D. Griffin

Evaluating Treatment Response of Chronic Myeloid Leukemia: Emerging Science and Technology

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 7
Page: 779-790
Authors: Antonia Cagnetta, Anna Garuti, Carlo Marani, Michele Cea, Maurizio Miglino, Ilaria Rocco, Claudia Palermo, Giuseppina Fugazza, Gabriella Cirmena, Nicoletta Colombo, Raffaella Grasso, Alessio Nencioni, Marco Gobbi and Franco Patrone

New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 7
Page: 711-723
Authors: Michele Cea, Antonia Cagnetta, Alessio Nencioni, Marco Gobbi and Franco Patrone

Advances in Immunotherapy of Chronic Myeloid Leukemia CML

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 7
Page: 768-774
Authors: Stefanie Andrea Erika Held, Annkristin Heine, Karin Tina Mayer, Mario Kapelle, Dominik Georg Friedrich Wolf and Peter Brossart

Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 7
Page: 749-754
Authors: Federica Galaverna, Chiara Ghiggi, Fabio Guolo, Germana Beltrami, Clara Dellepiane, Livia Giannoni, Andrea Carella and Angelo M. Carella

Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 7
Page: 755-767
Authors: Domenico Russo, Michele Malagola, Cristina Skert, Carla Filì, Cesare Bergonzi, Valeria Cancelli and Federica Cattina

Stem Cell Transplantation for Chronic Myeloid Leukemia (CML): Current Indications and Perspectives

Journal: Current Cancer Drug Targets
Volume: 13,Issue: 7
Page: 775-778
Authors: Andrea Bacigalupo

New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia

Journal: Current Cancer Drug Targets
Volume: 16,Issue: 4
Page: 323-345
Authors: Rui Huang, Qian Kang, Huimin Liu and Yuhua Li

In Vitro Anticancer Effects of Two New Potent Hydrazide Compounds on Leukemic Cells

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 16,Issue: 12
Page: 1646-1651
Authors: Shahrzad Tavakolfar, Elham Mousavi, Ali Almasirad, Amir Amanzadeh, Seyyed Mohamamd Atyabi, Parichehr Yaghamii, Somayeh Samiee-Sadr and Mona Salimi

Aryl Butenes Active against K562 Cells and Lacking Tyrosinase Inhibitory Activity as New Leads in the Treatment of Leukemia

Journal: Mini-Reviews in Medicinal Chemistry
Volume: 17,Issue:
Page: 1-8
Authors: Mehdi El Arbi, Emna Ketata, Aref Neifar, Wafa Mihoubi, Girish K. Gupta, Pascal Pigeon, Siden Top, Ali Gargouri and Gérard Jaouen

Design, Synthesis and Biological Evaluation of Betulinic Acid Derivatives as New Antitumor Agents for Leukemia

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 17,Issue: 13
Page: 1777-1785
Authors: Fernanda Waechter, Gloria N.S. da Silva, Julia B. Willig, Cristiane B. de Oliveira, Bruna D. Vieira, Daniela B.B. Trivella, Aline R. Zimmer, Andreia Buffon, Diogo A. Pilger and Simone C.B. Gnoatto*

Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms

Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 17,Issue: 3
Page: 161-166
Authors: Habib Haybar, Elahe Khodadi, Mohammad Shahjahani and Najmaldin Saki*

Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 18,Issue:
Page: 1-10
Authors: Tulin Ozkan, Yalda Hekmatshoar*, Tugba Ertan-Bolelli, Andry Nur Hidayat, Meral Beksac, Esin Aki-Yalcin, Ismail Yalcin and Asuman Sunguroglu

Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients

Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 18,Issue:
Page: 1-5
Authors: Marjanu Hikmah Elias, Husin Azlan, Abdul Aziz Baba and Ravindran Ankathil*